Full Press Release Details
Cybin to Participate in the 11th Annual LifeSci Partners Corporate Access Event and H.C. Wainwright
Bioconnect Conference
TORONTO, CANADA December 21, 2021 Cybin Inc. (NEO:CYBN) (NYSE
American:CYBN) ( Cybin or the Company ), a biopharmaceutical company focused on progressing Psychedelics to TherapeuticsTM is pleased to
announce that Doug Drysdale, Cybin s Chief Executive Officer, will participate in two upcoming virtual investor conferences as follows:
11th Annual LifeSci Partners Annual Corporate Access Event, January 5-7, 2022
Mr. Drysdale will participate in a panel discussion titled Psychedelics: More Than Just a Trip on Wednesday, January 5, 2022 at 10:00
a.m. ET. Please click here to register and access the webcast.
H.C. Wainwright Bioconnect Conference, January
Mr. Drysdale will participate in a fireside chat at the H.C. Wainwright Bioconnect Conference
being held virtually on Monday, January 10, 2022.
The fireside chat will be available on-demand beginning on
January 10, 2022 at 7:00 a.m. ET. To listen to the event, please click here to register and access the webcast. The archived webcast will also be available on the Company s investor relations website on the Events &
leading ethical biopharmaceutical company, working with a network of world-class partners and internationally recognized scientists, on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues.
Headquartered in Canada and founded in 2019, Cybin is operational in the United States, United Kingdom and Ireland. The Company is focused on progressing Psychedelics to Therapeutics by
engineering proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health disorders.
Investor & Media Contacts:
Vice President, Investor Relations